{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:11:56Z","timestamp":1784956316369,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1RO1AG047230"],"award-info":[{"award-number":["1RO1AG047230"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bisphosphonate (BP) therapy has been associated with atypical femur fracture (AFF). However, the threshold of treatment duration leading to increased AFF risk is unclear. In a retrospective cohort of older women initiating BP, we compared the AFF risk associated with treatment for at least three years to the risk associated with treatment less than three years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used observational data from a large population of female members of an integrated healthcare system who initiated oral BP during 2002\u20132014. Women were retrospectively followed for incident AFF confirmed by radiologic adjudication. Demographic data, pharmacologic exposures, comorbidity, bone density, and fracture history were ascertained from electronic health records. Inverse probability weighting was used to estimate risk differences comparing the cumulative incidence (risk) of AFF if women discontinued BP within three years to the cumulative incidence of AFF if women continued BP for three or more years, adjusting for potential time-dependent confounding by the aforementioned factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 87,820 women age 45\u201384\u2009years who initiated BP (mean age 68.6, median T-score\u2009\u2212\u20092.6, 14% with prior major osteoporotic fracture), 16,180 continued BP for three or more years. Forty-six confirmed AFFs occurred during follow-up in the two groups. AFF-free survival was greater for BP treatment &lt;\u20093\u2009years compared to treatment \u22653\u2009years (<jats:italic>p<\/jats:italic>\u00a0=\u20090.004 comparing areas under survival curves). At five years, the risk of AFF was 27 per 100,000 (95% confidence interval, CI: 8\u201346) if women received BP treatment &lt;\u20093\u2009years and 120 per 100,000 (95% CI: 56\u2013183) if women received BP treatment \u22653\u2009years (risk difference 93 per 100,000, 95% CI: 30\u2013160). By ten years, the risks were 27 (95% CI: 8\u201346) and 363 (95% CI: 132\u2013593) per 100,000 for BP treatment &lt;\u20093 and\u2009\u2265\u20093\u2009years, respectively (risk difference 336 per 100,000, 95% CI: 110\u2013570).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Bisphosphonate treatment for 3 or more years was associated with greater risk of AFF than treatment for less than 3\u2009years. Although AFFs are uncommon among BP-treated women, this increased risk should be considered when counseling women about long-term BP use. Future studies should further characterize the dose-response relationship between BP duration and incident AFF and identify patients at highest risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-020-03672-w","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T06:03:06Z","timestamp":1606975386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-0648","authenticated-orcid":false,"given":"Joan C.","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain S.","family":"Neugebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita L.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Grimsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika A.","family":"Izano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"1","key":"3672_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2014;29(1):1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"3672_CR2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3672_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349\u201353.","journal-title":"J Bone Joint Surg Br"},{"issue":"12","key":"3672_CR4","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","volume":"27","author":"RM Dell","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544\u201350.","journal-title":"J Bone Miner Res"},{"key":"3672_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12891-016-1086-8","volume":"17","author":"G Toro","year":"2016","unstructured":"Toro G, Ojeda-Thies C, Calabro G, et al. Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord. 2016;17:227.","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"3672_CR6","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s00198-019-05112-5","volume":"30","author":"JC Lo","year":"2019","unstructured":"Lo JC, Grimsrud CD, Ott SM, Chandra M, Hui RL, Ettinger B. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019;30(12):2515\u201320.","journal-title":"Osteoporos Int"},{"issue":"2","key":"3672_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333\u201368.","journal-title":"Endocr Rev"},{"issue":"1","key":"3672_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","volume":"86","author":"J Schilcher","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100\u20137.","journal-title":"Acta Orthop"},{"issue":"19","key":"3672_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761\u201371.","journal-title":"N Engl J Med"},{"key":"3672_CR10","first-page":"1","volume-title":"1997 Proceedings of the American Statistical Association. Section on Bayesian Statistical Science","author":"JM Robins","year":"1998","unstructured":"Robins JM. Marginal structural models. In:  1997 Proceedings of the American Statistical Association. Section on Bayesian Statistical Science. Alexandria: American Statistical Association; 1998. p. 1\u201310."},{"issue":"5","key":"3672_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology."},{"issue":"9","key":"3672_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3672_CR13","first-page":"503","volume":"23","author":"RL Hui","year":"2017","unstructured":"Hui RL, Adams AL, Niu F, et al. Predicting adherence and persistence with Oral bisphosphonate therapy in an integrated health care delivery system. J Manag Care Spec Pharm. 2017;23(4):503\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3672_CR14","first-page":"719","volume":"25","author":"MA Izano","year":"2019","unstructured":"Izano MA, Neugebauer R, Ettinger B, et al. Using pharmacy data and adherence to define long-term bisphosphonate exposure in women. J Manag Care Spec Pharm. 2019;25(6):719\u201323.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"3672_CR15","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1148\/rg.2018180073","volume":"38","author":"RA Marshall","year":"2018","unstructured":"Marshall RA, Mandell JC, Weaver MJ, Ferrone M, Sodickson A, Khurana B. Imaging features and management of stress, atypical, and pathologic fractures. Radiographics. 2018;38(7):2173\u201392.","journal-title":"Radiographics."},{"issue":"2","key":"3672_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39(2):224\u201331.","journal-title":"Injury."},{"issue":"5","key":"3672_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346\u201350.","journal-title":"J Orthop Trauma"},{"issue":"6","key":"3672_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00198-019-04869-z","volume":"30","author":"ES LeBlanc","year":"2019","unstructured":"LeBlanc ES, Rosales AG, Genant HK, et al. Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting. Osteoporos Int. 2019;30(6):1287\u201395.","journal-title":"Osteoporos Int"},{"issue":"1","key":"3672_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00198-016-3809-y","volume":"28","author":"AL Adams","year":"2017","unstructured":"Adams AL, Xue F, Chantra JQ, et al. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Osteoporos Int. 2017;28(1):413\u20137.","journal-title":"Osteoporos Int"},{"issue":"11","key":"3672_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267\u201394.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3672_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bone.2012.10.016","volume":"52","author":"J Schilcher","year":"2013","unstructured":"Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone. 2013;52(1):389\u201392.","journal-title":"Bone."},{"key":"3672_CR22","unstructured":"Ott SM. Bisphosphonates: Atypical femur fracture (subtrochanteric and shaft) X-ray gallery. Last updated (published) 2011, by Susan Ott, MD. In: Osteoporosis and bone physiology. UW Courses. Copyright 1998-2019, Susan Ott, MD. https:\/\/courses.washington.edu\/bonephys\/opsubtroch.html.Figure accessed 19 Sept 2020."},{"issue":"6","key":"3672_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3672_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Tamura MK, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"3672_CR25","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/sim.8503","volume":"39","author":"HA Blake","year":"2020","unstructured":"Blake HA, Leyrat C, Mansfield KE, et al. Propensity scores using missingness pattern information: a practical guide. Stat Med. 2020;39(11):1641\u201357.","journal-title":"Stat Med"},{"issue":"1","key":"3672_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1\u201321.","journal-title":"Stat Sci"},{"issue":"4","key":"3672_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455\u201366.","journal-title":"J Clin Densitom"},{"issue":"2","key":"3672_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1541-0420.2011.01685.x","volume":"68","author":"ID Munoz","year":"2012","unstructured":"Munoz ID, van der Laan M. Population intervention causal effects based on stochastic interventions. Biometrics. 2012;68(2):541\u20139.","journal-title":"Biometrics."},{"issue":"1","key":"3672_CR29","doi-asserted-by":"publisher","first-page":"20160015","DOI":"10.1515\/jci-2016-0015","volume":"5","author":"R Neugebauer","year":"2017","unstructured":"Neugebauer R, Schmittdiel JA, Adams AS, Grant RW, van der Laan MJ. Identification of the joint effect of a dynamic treatment intervention and a stochastic monitoring intervention under the no direct effect assumption. J Causal Inference. 2017;5(1):20160015.","journal-title":"J Causal Inference"},{"issue":"2","key":"3672_CR30","first-page":"161","volume":"9","author":"I Diaz","year":"2013","unstructured":"Diaz I, van der Laan MJ. Assessing the causal effect of policies: an example using stochastic interventions. Int J Biostat. 2013;9(2):161\u201374.","journal-title":"Int J Biostat"},{"key":"3672_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511803161","volume-title":"Causality: models, reasoning, and inference","author":"J Pearl","year":"2009","unstructured":"Pearl J. Causality: models, reasoning, and inference. 2nd ed. New York: Cambridge University Press; 2009.","edition":"2"},{"issue":"23","key":"3672_CR32","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1002\/sim.3301","volume":"27","author":"J Robins","year":"2008","unstructured":"Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27(23):4678\u2013721.","journal-title":"Stat Med"},{"issue":"8","key":"3672_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"key":"3672_CR34","unstructured":"Kaiser Permanente Northern California Division of Research, Leong TK, Tabada GH, Yang J, Zhu Z, Neugebauer R. MSMstructure. Updated March 2017. https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/biostatistics\/causalinferencesoftware. Accessed 10 Oct 2020."},{"issue":"14","key":"3672_CR35","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/sim.6099","volume":"33","author":"R Neugebauer","year":"2014","unstructured":"Neugebauer R, Schmittdiel JA, van der Laan MJ. Targeted learning in real-world comparative effectiveness research with time-varying interventions. Stat Med. 2014;33(14):2480\u2013520.","journal-title":"Stat Med"},{"issue":"1","key":"3672_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1515\/ijb-2015-0028","volume":"12","author":"R Neugebauer","year":"2016","unstructured":"Neugebauer R, Schmittdiel JA, van der Laan MJ. A case study of the impact of data-adaptive versus model-based estimation of the propensity scores on causal inferences from three inverse probability weighting estimators. Int J Biostat. 2016;12(1):131\u201355.","journal-title":"Int J Biostat"},{"issue":"6","key":"3672_CR37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"3672_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0962280210386207","volume":"21","author":"ML Petersen","year":"2012","unstructured":"Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ. Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res. 2012;21(1):31\u201354.","journal-title":"Stat Methods Med Res"},{"issue":"16","key":"3672_CR39","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/sim.8164","volume":"38","author":"O Sofrygin","year":"2019","unstructured":"Sofrygin O, Zhu Z, Schmittdiel JA, et al. Targeted learning with daily EHR data. Stat Med. 2019;38(16):3073\u201390.","journal-title":"Stat Med"},{"key":"3672_CR40","unstructured":"Sofrygin O, van der Laan MJ, Neugebauer R. R\/stremr: Streamlined Causal Inference for Static, Dynamic and Stochastic Regimes in Longitudinal Data. https:\/\/github.com\/osofr\/stremr. Accessed 10 Oct 2020."},{"key":"3672_CR41","unstructured":"The R Project for Statistical Computing. The R Foundation. https:\/\/www.r-project.org\/. ."},{"issue":"22","key":"3672_CR42","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med. 2012;366(22):2048\u201351.","journal-title":"N Engl J Med"},{"key":"3672_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo JC, Hui RL, Grimsrud CD, et al. The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016;85:142\u20137.","journal-title":"Bone."},{"issue":"9041","key":"3672_CR44","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535\u201341.","journal-title":"Lancet"},{"issue":"24","key":"3672_CR45","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927\u201338.","journal-title":"JAMA."},{"issue":"24","key":"3672_CR46","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA. 1998;280(24):2077\u201382.","journal-title":"JAMA."},{"issue":"4","key":"3672_CR47","first-page":"711","volume":"101","author":"MM Luckey","year":"2003","unstructured":"Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol. 2003;101(4):711\u201321.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"3672_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","volume":"16","author":"J Starr","year":"2018","unstructured":"Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep. 2018;16(4):519\u201329.","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"3672_CR49","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"3672_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines Committee of the American College of P. treatment of low Bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818\u201339.","journal-title":"Ann Intern Med"},{"issue":"10","key":"3672_CR51","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/jbmr.2918","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(10):1910.","journal-title":"J Bone Miner Res"},{"key":"3672_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Paschou SA, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23\u201330.","journal-title":"Maturitas."}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-020-03672-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T06:03:46Z","timestamp":1606975426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03672-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03672-w","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"5 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Kaiser Permanente Northern California Institutional Review Board and the requirement for informed consent was waived due to the nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"801"}}